Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 29, 2024

Experts Share Final Insights to Optimize Atopic Dermatitis Patient Care

In their concluding remarks, the expert panel shares insights and provides recommendations to help practicing clinicians optimize atopic dermatitis patient care.

Episodes in this series

Video features 3 KOLs

EP. 1 Tackling Key Concerns in Atopic Dermatitis + Biologic Use

Video features 3 KOLs

EP. 2 Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape

Video features 3 KOLs

EP. 3 Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment

Video features 3 KOLs

EP. 4 Experts Discuss Long-Term Effects and Monitoring in AD Therapy

Video features 3 KOLs

EP. 5 Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD

Video features 3 KOLs

EP. 6 The Patient Journey: Effectively Managing AD Itch Early On

Video features 3 KOLs

EP. 7 Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies

Video features 3 KOLs

EP. 8 Experts Share Final Insights to Optimize Atopic Dermatitis Patient Care

Please provide your final thoughts from each of you, including key insights that you’re taking away from this discussion.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Irina Murakhovskaya | Image Credit: Montefiore Einstein

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

ByBrooke McCormick,Irina Murakhovskaya, MD

June 26th 2026

CRC animation | Image Credit: Thipphaphone - stock.adobe.com

Early-Life, Parental Factors May Help Explain Rising Early-Onset CRC Rates

ByBrooke McCormick

June 26th 2026

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

HR-Positive Breast Cancer: Clinical Use of Oral SERDs in Combination vs Monotherapy

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.

HR-Positive Breast Cancer: Evolving Role of ESR1 Mutations in Endocrine Resistance

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

Stamp that says "FDA Approved" in blue ink. | Image Credit: Surendra - stock.adobe.com

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

ByElla Hohmann, MS

June 25th 2026

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers

Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma

Health Equity & Access Weekly Roundup: June 26, 2026

Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis